DeDora Capital Inc. Boosts Stake in Eli Lilly and Company (NYSE:LLY)

DeDora Capital Inc. lifted its holdings in Eli Lilly and Company (NYSE:LLY) by 21.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,152 shares of the company’s stock after buying an additional 375 shares during the period. DeDora Capital Inc.’s holdings in Eli Lilly and Company were worth $1,674,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of LLY. Legacy Financial Group LLC purchased a new position in shares of Eli Lilly and Company in the third quarter worth about $35,000. Baker Ellis Asset Management LLC acquired a new position in Eli Lilly and Company in the 3rd quarter valued at about $215,000. Mn Services Vermogensbeheer B.V. boosted its holdings in Eli Lilly and Company by 1.4% in the 3rd quarter. Mn Services Vermogensbeheer B.V. now owns 353,388 shares of the company’s stock valued at $189,815,000 after purchasing an additional 5,000 shares during the last quarter. Guyasuta Investment Advisors Inc. boosted its holdings in Eli Lilly and Company by 0.8% in the 3rd quarter. Guyasuta Investment Advisors Inc. now owns 3,047 shares of the company’s stock valued at $1,637,000 after purchasing an additional 23 shares during the last quarter. Finally, Segment Wealth Management LLC boosted its holdings in Eli Lilly and Company by 5.4% in the 3rd quarter. Segment Wealth Management LLC now owns 1,278 shares of the company’s stock valued at $686,000 after purchasing an additional 65 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Down 2.8 %

Shares of NYSE:LLY traded down $20.94 during trading hours on Friday, reaching $734.97. The stock had a trading volume of 4,595,138 shares, compared to its average volume of 2,629,045. Eli Lilly and Company has a 1 year low of $419.80 and a 1 year high of $800.78. The firm’s 50 day moving average is $761.06 and its 200-day moving average is $671.38. The company has a debt-to-equity ratio of 1.90, a quick ratio of 0.73 and a current ratio of 1.35. The stock has a market capitalization of $698.52 billion, a price-to-earnings ratio of 108.24, a P/E/G ratio of 1.50 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The business had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. During the same quarter in the prior year, the business posted $1.62 EPS. The company’s revenue for the quarter was up 26.0% on a year-over-year basis. Research analysts predict that Eli Lilly and Company will post 13.83 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. BMO Capital Markets boosted their target price on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an “outperform” rating in a report on Wednesday. DZ Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price on the stock. in a report on Wednesday, February 21st. Truist Financial boosted their target price on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the company a “buy” rating in a report on Wednesday. Cantor Fitzgerald reissued an “overweight” rating and issued a $885.00 price target (up from $815.00) on shares of Eli Lilly and Company in a research note on Tuesday. Finally, Wells Fargo & Company boosted their price target on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $757.95.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.